Ricevi le ultime notizie sulle azioni Karyopharm Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di KPTI

Ultime notizie per

KARYOPHARM THERAPEUTICS INC

Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics Inc

Press Releases

Karyopharm to Present at the Jefferies Global Healthcare Conference

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

Earnings

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis

Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025

KPTI

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

aTyr Pharma

Biomea Fusion

Clene

Connect Biopharma Holdings Limited - Ordinary Shares

Connect Biopharma Hldgs

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

InflaRx

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Macrogenics

Metagenomi

OKYO Pharma

Ovid Therapeutics

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Pelthos Therapeutics

Quince Therapeutics

AVITA Medical

Sutro Biopharma

Shattuck Labs

TScan Therapeutics

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Comments

Karyopharm Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO